Mufson M A, Hughey D F, Turner C E, Schiffman G
Department of Medicine, Marshall University School of Medicine, Huntington, WV 25701.
Vaccine. 1991 Jun;9(6):403-7. doi: 10.1016/0264-410x(91)90126-q.
We vaccinated 15 persons, age 56 to 79 years, with 14-valent pneumococcal polysaccharide vaccine and revaccinated them with 23-valent vaccine 6 years later to assess adverse reactions and booster responses of anticapsular antibodies. No systemic reactions occurred after administration of either vaccine. After booster vaccination, five vaccinees developed only mild soreness or tenderness at the site of injection. The (arithmetic) mean antibody level to 12 capsular types measured by radioimmunoassay increased 3.1-fold 1 month after the first vaccine; the range was 1427-5124 ng antibody nitrogen per ml (N ml-1). Six years later, mean antibody levels waned to about half these levels. One month after administration of the second dose of vaccine, the mean antibody level increased 1.5-fold; the range was 1011-3954 ng antibody N ml-1. Revaccination with pneumococcal vaccine of elderly persons can be carried out safely; the levels of anticapsular antibody achieved after revaccination are about half the levels after primary vaccination.
我们为15名年龄在56至79岁之间的人接种了14价肺炎球菌多糖疫苗，并在6年后用23价疫苗对他们进行再接种，以评估不良反应和抗荚膜抗体的加强反应。两种疫苗接种后均未出现全身反应。加强接种后，5名接种者仅在注射部位出现轻微疼痛或压痛。通过放射免疫测定法测量的针对12种荚膜型的（算术）平均抗体水平在首次接种疫苗后1个月增加了3.1倍；范围为每毫升1427 - 5124纳克抗体氮（N ml-1）。6年后，平均抗体水平降至这些水平的约一半。在接种第二剂疫苗1个月后，平均抗体水平增加了1.5倍；范围为1011 - 3954纳克抗体N ml-1。对老年人进行肺炎球菌疫苗再接种可以安全进行；再接种后获得的抗荚膜抗体水平约为初次接种后的一半。
